EXPLORE YOUR NEXT CHAPTER
Director, Global Value & Market Access HEOR - 1 year temporary contract
Alfasigma
Source: Headcount Labs · original listing ↗
Job data: Headcount Labs, ODbL 1.0. Job descriptions belong to their employers.
Posted Oct 22
About this role
Alfasigma is a privately held global healthcare company founded over 75 years ago in Italy, where it remains headquartered today in Bologna and Milan. The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa. Over three years ago, we embarked on a transformative journey to become a truly global innovative healthcare company with a leading focus on Gastrointestinal (GI) health . We have experienced remarkable growth, nearly doubled our revenues, expanding geographically, and integrating several key acquisitions. We have also evolved our portfolio, expanded into rare and specialty segments, and strengthened our pipeline and people's capabilities. But our journey is far from complete! In fact, this is just the beginning of a bold new chapter in Alfasigma's history. We are committed to advancing innovation and leveraging our deep expertise to provide better health and a better quality of life for patients and consumers worldwide and expand our reach across diverse markets. Scope of The Role This pivotal global role within the Global Value & Market Access team leads the development and delivery of clinical and health economic payer evidence and oversees the delivery of systematic literature reviews, targeted literature reviews, indirect treatment comparisons, health economic models, budget impact analyses, and the input on integrated payer evidence generation plans. Working in close partnership with the cross-functional stakeholders, the role ensures that robust comparative clinical and economic evidence supports asset strategy, HTA submissions, pricing, reimbursement, and lifecycle planning from early development through launch and beyond. Your Role 1. Drive Payer Evidence Generation and Value Demonstration • Lead the design, execution, quality assurance, and timely delivery of systematic literature reviews and targeted literature reviews across clinical efficacy, safety, epidemiology, burden of illness, health-related quality of life, resource use, costs, and treatment patterns. • Partner with Clinical Development, Medical Affairs, Regulatory Affairs, and R&D to ensure evidence strategies support pricing, reimbursement, and access objectives. • Lead initiatives to generate robust clinical, economic, patient-reported, and real-world evidence supporting payer value demonstration. • Ensure asset evidence packages address payer, healthcare system, patient, societal, and policy stakeholder needs. • Provide strategic input into development of lifecycle management programs to optimize future market access, pricing, reimbursement, and HTA outcomes. 2. Develop Global Value Communication and HTA Support Materials • Lead the development and continuous enhancement of global value communication materials, including: • Global Value Dossiers • Payer Value Proposition and Story • Objection Handlers • Disease Area Reviews • Drive the preparation of evidence packages supporting HTA assessments, reimbursement negotiations, and value communication. • Coordinate health economic models, budget impact analyses, and comparative effectiveness assessments. • Support local affiliates in adapting global tools to country-specific requirements. • Establish best-practice standards and methodologies for market access excellence across the organization. 3. Act as a Strategic Health Policy Partner • Serve as a trusted advisor and subject matter expert on global market access, pricing, HTA, and health policy. • Provide thought leadership on evolving payer trends, HTA developments, healthcare reforms, and rare disease policy initiatives. • Influence cross-functional decision-making by integrating payer, policy, and access perspectives into strategic discussions. • Build strong partnerships across Commercial, Medical, Regulatory, R&D, HEOR, and external stakeholders to optimize patient access and asset value. • Identify and assess emerging policy, reimbursement, and access trends that may impact portfolio strategy and future growth opportunities. Who you are Work Experience • 10+ years of experience in HEOR, evidence synthesis, health economic modelling, HTA, or related evidence-generation roles within the pharmaceutical, biotechnology, or specialized consulting sectors. • Demonstrated experience developing global pricing, reimbursement, market access, and value strategies for specialty and/or rare disease assets. • Experience across multiple stages of the product lifecycle, including pre-launch, launch, lifecycle management, and loss-of-exclusivity planning. • Strong understanding of global payer systems and healthcare policy, including US market access and HTA-driven reimbursement environments in Europe and other major markets. • Proven experience in evidence generation, health economics, outcomes research and HTA submissions. • Experience assessing the impact of health policy, HTA, and reimbursement reforms on asset strategy and market access outcomes. • Proven ability to influence cross-functional decision-making and lead collaboration across Medical Affairs, Regulatory Affairs, Clinical Development, R&D, and other global functions. • Experience in rare diseases, orphan drugs, or specialty care is strongly preferred. • Experience engaging with external stakeholders, including HTA agencies, payers and policymakers. Why Join Alfasigma: At Alfasigma, we foster a culture where the courage to innovate is key to our success. We offer a competitive salary, comprehensive benefits, and extensive opportunities for professional growth and development. Our commitment to people and patients is at the heart of everything we do. We value diversity and welcome individuals with unique perspectives and experiences. We believe that open-mindedness, collaboration, and a shared passion for innovation are essential to achieving meaningful progress. Join Alfasigma and become part of a forward-thinking team dedicated to shaping the future of the pharmaceutical industry.